A detailed history of Bok Financial Private Wealth, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bok Financial Private Wealth, Inc. holds 2,357 shares of VRTX stock, worth $959,558. This represents 0.08% of its overall portfolio holdings.

Number of Shares
2,357
Previous 2,593 9.1%
Holding current value
$959,558
Previous $1.22 Million 9.79%
% of portfolio
0.08%
Previous 0.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$460.0 - $505.78 $108,560 - $119,364
-236 Reduced 9.1%
2,357 $1.1 Million
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $8,641 - $10,681
-22 Reduced 0.84%
2,593 $1.22 Million
Q1 2024

Apr 30, 2024

SELL
$407.69 - $446.08 $194,060 - $212,334
-476 Reduced 15.4%
2,615 $1.09 Million
Q4 2023

Jan 30, 2024

SELL
$343.0 - $410.68 $111,475 - $133,471
-325 Reduced 9.51%
3,091 $1.26 Million
Q3 2023

Oct 13, 2023

SELL
$338.18 - $362.46 $272,573 - $292,142
-806 Reduced 19.09%
3,416 $1.19 Million
Q2 2023

Aug 08, 2023

SELL
$314.42 - $351.91 $241,160 - $269,914
-767 Reduced 15.37%
4,222 $1.49 Million
Q1 2023

Apr 21, 2023

BUY
$283.23 - $323.1 $171,070 - $195,152
604 Added 13.77%
4,989 $1.57 Million
Q4 2022

Feb 02, 2023

BUY
$285.76 - $321.48 $1.25 Million - $1.41 Million
4,385 New
4,385 $1.27 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $330,118 - $411,032
-1,405 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$221.42 - $260.97 $78,604 - $92,644
355 Added 33.81%
1,405 $367,000
Q4 2021

Feb 15, 2022

BUY
$177.01 - $223.45 $185,860 - $234,622
1,050 New
1,050 $231,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Bok Financial Private Wealth, Inc. Portfolio

Follow Bok Financial Private Wealth, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bok Financial Private Wealth, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bok Financial Private Wealth, Inc. with notifications on news.